Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameIbuprofen
Accession NumberDB01050  (APRD00372)
Typesmall molecule
Groupsapproved
Description

Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

Structure
Thumb
Synonyms
SynonymLanguageCode
IbuprophenNot AvailableNot Available
P-Isobutylhydratropic AcidNot AvailableNot Available
Para-Isobutylhydratropic AcidNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
Act-3Not Available
ActiprofenNot Available
AdexNot Available
AdranNot Available
AdvilNot Available
Advil Liqui-GelsNot Available
AktrenNot Available
AlaxanNot Available
Alges-XNot Available
AlgoflexNot Available
AlgofrenNot Available
AliviumNot Available
AmersolNot Available
AmibufenNot Available
Anadin IbuprofenNot Available
Anadin Joint PainNot Available
AncoNot Available
AnflagenNot Available
ApsifenNot Available
Apsifen-FNot Available
ArthrofenNot Available
ArtofenNot Available
BetagesicNot Available
BetaprofenNot Available
BlutonNot Available
BonifenNot Available
BrufenNot Available
BrufortNot Available
BuburoneNot Available
BugesicNot Available
BuprovilNot Available
BuranaNot Available
ButyleninNot Available
CaldolorNot Available
CalprofenNot Available
Cap-ProfenPERRIGO
Children's AdvilPfizer
Children's ElixsurePfizer
Children's IbuprofenPfizer
Children's MotrinNot Available
DalsyNot Available
DismenolNot Available
DiverinNot Available
DolgiridNot Available
DolgitNot Available
Dolo-DolgitNot Available
Dolo-SpedifenNot Available
DolofortNot Available
DolorazNot Available
DolorminNot Available
DorivalNot Available
EbufacNot Available
EmuProfenNot Available
EpobronNot Available
EspidifenNot Available
EveNot Available
FemadonNot Available
FenbidNot Available
FenpaedNot Available
FinalflexNot Available
GalprofenNot Available
HaltranNot Available
Herron BlueNot Available
i-profen Not Available
IbalginNot Available
Ibu-AttritinNot Available
IBU-RatiopharmNot Available
Ibu-VivimedNot Available
IbuflamNot Available
IbugelNot Available
IbugesicNot Available
IbuHEXALNot Available
IbuleveNot Available
IbumNot Available
IbumaxNot Available
IbumetinNot Available
IbumidolNot Available
IbupainNot Available
IbuprocinNot Available
IbupromNot Available
IbuprosynNot Available
IbuproxNot Available
IbustarNot Available
IbutidNot Available
IbuxNot Available
IbuxinNot Available
InabrinNot Available
InovenNot Available
IprenNot Available
Junior Strength AdvilNot Available
Junior Strength IbuprofenNot Available
Junior Strength MotrinNot Available
KratalginNot Available
LamidonNot Available
LebrufenNot Available
LiptanNot Available
LotemNot Available
MedicolNot Available
MediprenNot Available
Midol IBNot Available
MotrinNot Available
MynosedinNot Available
MypaidNot Available
MyprodolNot Available
NarfenNot Available
Naron Ace Not Available
NeobrufenNot Available
NeoProfenOvation
NobfenNot Available
NobgenNot Available
NorvectanNot Available
NuprinNot Available
NureflexNot Available
NurofenNot Available
OrbifenNot Available
PanafenNot Available
PediaprofenNot Available
PerifarNot Available
ProfinNot Available
RanfenNot Available
RapidolNot Available
RatiodolorNot Available
RimafenNot Available
RoideninNot Available
RufenNot Available
SalvarinaNot Available
SeclodinNot Available
SolpaflexNot Available
SpedifenNot Available
Speedpain NANONot Available
SpidifenNot Available
SusprenNot Available
TabalonNot Available
TefinNot Available
TrendarNot Available
UnafenNot Available
UpfenNot Available
UremNot Available
Brand mixtures
Brand NameIngredients
Advil Cold & Sinusibuprofen + pseudoephedrine HCl
Advil Cold & Sinus Daytimeibuprofen + pseudoephedrine HCl
Advil Cold and Sinus Nighttimeibuprofen + pseudoephedrine HCll + chlorpheniramine maleate
Advil Cold and Sinus Plusibuprofen + pseudoephedrine HCl + chlorpheniramine maleate
Advil Flu & Body Acheibuprofen + pseudoephedrine HCl
Children's Advil Coldibuprofen + pseudoephedrine HCl
Dristan Sinus Capletsibuprofen + pseudoephedrine HCl
Motrin Children's Coldibuprofen + pseudoephedrine HCl
Motrin Sinus Headacheibuprofen + pseudoephedrine HCl
Robax Platinummethocarbamol + ibuprofen
Sudafed Sinus Advanceibuprofen + pseudoephedrine HCl
Vicoprofenibuprofen + hydrocodone bitartrate
Categories
CAS number15687-27-1
WeightAverage: 206.2808
Monoisotopic: 206.13067982
Chemical FormulaC13H18O2
InChI KeyInChIKey=HEFNNWSXXWATRW-UHFFFAOYSA-N
InChI
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
IUPAC Name
2-[4-(2-methylpropyl)phenyl]propanoic acid
SMILES
CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Mass Specshow(11.4 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassPhenylpropanoids and Polyketides
ClassPhenylpropanoic Acids
SubclassNot Available
Direct parentPhenylpropanoic Acids
Alternative parentsAromatic Monoterpenes; Phenylacetic Acid Derivatives; Monocyclic Monoterpenes; Enolates; Carboxylic Acids; Polyamines
Substituentsbenzene; polyamine; enolate; carboxylic acid; carboxylic acid derivative
Classification descriptionThis compound belongs to the phenylpropanoic acids. These are compounds whose structure contain a benzene ring conjugated to a propanoic acid.
Pharmacology
IndicationFor symptomatic treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis. May be used to treat mild to moderate pain and for the management of dysmenorrhea. May be used to reduce fever. Has been used with some success for treating ankylosing spondylitis, gout and psoriatic arthritis. May reduce pain, fever and inflammation of pericarditis. May be used IV with opiates to relieve moderate to severe pain. Ibuprofen lysine may be used IV to treat patent ductus arteriosus (PDA) in premature neonates.
PharmacodynamicsIbuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis.
Mechanism of actionThe exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.
Absorption~ 80% absorbed from GI tract

Time to reach peak plasma concentration = 47 minutes (suspension), 62 minutes (chewable tablets), 120 minutes (conventional tablets)

Volume of distributionNot Available
Protein binding90-99% to whole human plasma and site II of purified albumin, binding appears to be saturable and becomes non-linear at concentrations exceeding 20 mcg/ml.
Metabolism

R-enanatiomer undergoes extensive enantiomeric conversion (53-65%) to the more active S-enantiomer <i>in vivo</i>. Metablized by oxidation to 2 inactive metabolites: (+)-2[4´-(2-hydroxy-2-methylpropyl)phenyl]propionic acid and (+)-2-[4´-(2-carboxypropyl)phenyl]propionic acid. Very small amounts of 1-hydroxyibuprofen and 3-hydroxyibuprofen have been recovered from urine. Cytochrome P450 2C9 is the major catalyst in the formation of oxidative metabolites. Oxidative metabolites may be conjugated to glucuronide prior to excretion.

SubstrateEnzymesProduct
Ibuprofen
Ibuprofen glucuronideDetails
Ibuprofen
2-HydroxyibuprofenDetails
Ibuprofen
3-HydroxyibuprofenDetails
Ibuprofen
    1-hydroxyibuprofenDetails
    3-Hydroxyibuprofen
    Carboxy-ibuprofenDetails
    Route of eliminationIbuprofen is rapidly metabolized and eliminated in the urine.
    Half life2-4 hours
    ClearanceNot Available
    Toxicity

    Side effects: May cause peripheral edema and fluid retention. Use caution in patients with congestive heart failure or severe uncontrolled hypertension. May cause dyspepsia, heartburn, nausea, vomiting, anorexia, diarrhea, constipation, stomatitis, flatulence, bloating, epigastric pain, and abdominal pain. Peptic ulcer and GI bleeding have been reported. May also cause dizziness, headache and nervousness. Acute renal failure accompanied by acute tubular necrosis has been reported.

    Most common symptoms of overdose are abdominal pain, nausea, vomiting, lethargy, vertigo, drowsiness (somnolence), dizziness and insomnia. Other symptoms of overdose include headache, loss of consciousness, tinnitus, CNS depression, convulsions and seizures. May rarely cause metabolic acidosis, abnormal hepatic function, hyperkalemia, renal failure, dyspnea, respiratory depression, coma, acute renal failure, and apnea (primarily in very young pediatric patients).

    LD50=1255mg/kg(orally in mice)

    Affected organisms
    • Humans and other mammals
    PathwaysNot Available
    SNP Mediated EffectsNot Available
    SNP Mediated Adverse Drug ReactionsNot Available
    ADMET
    Predicted ADMET features
    Property Value Probability
    Human Intestinal Absorption + 0.9927
    Blood Brain Barrier + 0.9619
    Caco-2 permeable + 0.8866
    P-glycoprotein substrate Non-substrate 0.759
    P-glycoprotein inhibitor I Non-inhibitor 0.9705
    P-glycoprotein inhibitor II Non-inhibitor 0.9323
    Renal organic cation transporter Non-inhibitor 0.9323
    CYP450 2C9 substrate Non-substrate 0.7594
    CYP450 2D6 substrate Non-substrate 0.9116
    CYP450 3A4 substrate Non-substrate 0.6877
    CYP450 1A2 substrate Non-inhibitor 0.9045
    CYP450 2C9 substrate Non-inhibitor 0.9305
    CYP450 2D6 substrate Non-inhibitor 0.9231
    CYP450 2C19 substrate Non-inhibitor 0.9881
    CYP450 3A4 substrate Non-inhibitor 0.9655
    CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9691
    Ames test Non AMES toxic 0.9894
    Carcinogenicity Carcinogens 0.5553
    Biodegradation Ready biodegradable 0.5142
    Rat acute toxicity 2.3092 LD50, mol/kg Not applicable
    hERG inhibition (predictor I) Weak inhibitor 0.9719
    hERG inhibition (predictor II) Non-inhibitor 0.9734
    Pharmacoeconomics
    Manufacturers
    • Wyeth consumer healthcare
    • Banner pharmacaps inc
    • Contract pharmacal corp
    • Dr reddys laboratories ltd
    • Marksans pharma ltd
    • Bayer healthcare llc
    • Cumberland pharmaceuticals inc
    • Mcneil consumer healthcare
    • Perrigo co
    • Tris pharma inc
    • Mcneil consumer products co div mcneilab inc
    • Alterna tchp llc
    • L perrigo co
    • Abbott laboratories pharmaceutical products div
    • Actavis mid atlantic llc
    • Perrigo r and d co
    • Mcneil consumer healthcare div mcneil ppc inc
    • Mcneil pediatrics
    • Lederle laboratories div american cyanamid co
    • Basf corp
    • Pliva inc
    • Advent pharmaceuticals inc
    • Amneal pharmaceuticals ny llc
    • Dr reddys laboratories louisiana llc
    • Dr reddys laboratories inc
    • Halsey drug co inc
    • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
    • Leiner health products inc
    • Lnk international inc
    • Mutual pharmaceutical co inc
    • Mylan pharmaceuticals inc
    • Mylan laboratories inc
    • Northstar healthcare holdings ltd
    • Ohm corp
    • Ohm laboratories inc
    • Par pharmaceutical inc
    • Purepac pharmaceutical co
    • Sandoz inc
    • Shasun usa inc
    • Superpharm corp
    • Teva pharmaceuticals usa inc
    • Vintage pharmaceuticals inc
    • Watson laboratories inc
    • Alra laboratories inc
    • Bristol myers products inc
    • Lundbeck inc
    Packagers
    Dosage forms
    FormRouteStrength
    CapsuleOral200 mg
    ConcentrateIntravenous100 mg/ml
    SuspensionOral100 mg/5 ml
    SuspensionOral40 mg/ml
    TabletOral200 mg
    TabletOral400 mg
    TabletOral600 mg
    TabletOral800 mg
    Tablet, chewableOral100 mg
    Tablet, chewableOral50 mg
    Tablet, film coatedOral100 mg
    Tablet, film coatedOral200 mg
    Tablet, film coatedOral400 mg
    Tablet, film coatedOral600 mg
    Tablet, film coatedOral800 mg
    Prices
    Unit descriptionCostUnit
    Neoprofen 20 mg/2 ml vial304.5USDml
    Caldolor 400 mg/4 ml vial2.21USDml
    Caldolor 800 mg/8 ml vial1.58USDml
    Nuprin arthritis patch1.11USDpatch
    Ibuprofen powder1.04USDg
    Nuprin muscle & joint patch1.03USDpatch
    Profen II 45-800 mg 12 Hour tablet0.69USDtablet
    Motrin 800 mg tablet0.59USDtablet
    Advil allergy sinus caplet0.5USDcaplet
    Ibu-drops 40 mg/ml suspension drops0.42USDml
    Motrin 600 mg tablet0.4USDtablet
    Ibuprofen 800 mg tablet0.36USDtablet
    Ibuprofen 400 mg tablet0.35USDtablet
    Infant's motrin 50 mg/1.25 ml0.34USDml
    Childs ibuprofen susp drp0.33USDml
    Ibuprofen 600 mg tablet0.33USDtablet
    Wal-profen cold & sinus cplt0.3USDcaplet
    Infant ibuprofen susp drop0.29USDml
    Motrin 400 mg tablet0.29USDtablet
    CVS Pharmacy infant ibuprofen susp drop0.25USDml
    Infants medi-profen susp0.23USDml
    Advil cold & sinus caplet0.22USDcaplet
    Advil pm caplet0.22USDcaplet
    Soba profen cold-sinus tablet0.22USDtablet
    Midol caplet0.21USDcaplet
    Advil migraine 200 mg capsule0.2USDcapsule
    Ibuprofen cold-sinus caplet0.2USDcaplet
    Motrin 100 mg caplet0.2USDcaplet
    Motrin pm caplet0.2USDcaplet
    Advil 200 mg liqui-gel capsule0.19USDcapsule
    Soba profen ib caplet0.19USDcaplet
    Motrin 100 mg tablet chew0.18USDtablet
    Pub infants profenib drops0.18USDml
    Sm ibuprofen ib 100 mg tablet0.18USDtablet
    Eck ibuprofen jr caplet0.17USDcaplet
    Ibuprofen pm caplet0.17USDcaplet
    Advil 200 mg caplet0.15USDcapsule
    Advil 200 mg gel caplet0.15USDcaplet
    Advil 200 mg tablet0.15USDtablet
    Ibuprofen 100 mg tablet chew0.15USDtablet
    Motrin ib 200 mg caplet0.15USDcaplet
    Apo-Ibuprofen 600 mg Tablet0.14USDtablet
    CVS Pharmacy ibuprofen jr str 100 mg tablet0.14USDtablet
    Nu-Ibuprofen 600 mg Tablet0.14USDtablet
    Motrin ib 200 mg tablet0.13USDtablet
    Motrin ib 200 mg gelcap0.12USDcapsule
    Nuprin 200 mg caplet0.12USDcaplet
    Wal-profen 200 mg caplet0.12USDcaplet
    Wal-profen 200 mg tablet0.12USDtablet
    Eql ibuprofen 200 mg tablet0.1USDtablet
    Nuprin 200 mg tablet0.1USDtablet
    Apo-Ibuprofen 400 mg Tablet0.08USDtablet
    Ibuprofen ib 200 mg tablet0.08USDtablet
    Novo-Profen 400 mg Tablet0.08USDtablet
    Apo-Ibuprofen 300 mg Tablet0.07USDtablet
    Medi-profen 200 mg tablet0.07USDtablet
    Ibuprofen 100 mg/5ml Suspension0.06USDml
    Ibuprofen 200 mg caplet0.06USDcaplet
    Child ibuprofen susp0.05USDml
    Children's medi-profen susp0.05USDml
    Children's motrin cold suspension0.05USDml
    CVS Pharmacy ibuprofen 200 mg tablet0.05USDtablet
    Ibuprofen cold suspension0.05USDml
    I-prin 200 mg tablet0.05USDtablet
    Novo-Profen 600 mg Tablet0.05USDtablet
    Children's motrin cold0.04USDml
    Pv ibuprofen 200 mg caplet0.04USDcaplet
    Soba children's profenib susp0.04USDml
    Ibuprofen 200 mg tablet0.03USDtablet
    CVS Pharmacy ibuprofen 200 mg caplet0.02USDcaplet
    Pv ibuprofen 200 mg tablet0.02USDtablet
    DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
    Patents
    CountryPatent NumberApprovedExpires (estimated)
    United States67272862001-11-272021-11-27
    United States52157551993-06-012010-06-01
    Properties
    Statesolid
    Experimental Properties
    PropertyValueSource
    melting point76 °CPhysProp
    water solubility21 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
    logP3.97AVDEEF,A (1997)
    logS-3.99ADME Research, USCD
    Caco2 permeability-4.28ADME Research, USCD
    pKa4.91SANGSTER (1994)
    Predicted Properties
    PropertyValueSource
    water solubility6.84e-02 g/lALOGPS
    logP3.5ALOGPS
    logP3.84ChemAxon
    logS-3.5ALOGPS
    pKa (strongest acidic)4.85ChemAxon
    physiological charge-1ChemAxon
    hydrogen acceptor count2ChemAxon
    hydrogen donor count1ChemAxon
    polar surface area37.3ChemAxon
    rotatable bond count4ChemAxon
    refractivity60.73ChemAxon
    polarizability23.76ChemAxon
    number of rings1ChemAxon
    bioavailability1ChemAxon
    rule of fiveYesChemAxon
    Ghose filterYesChemAxon
    Veber's ruleYesChemAxon
    MDDR-like ruleNoChemAxon
    Spectra
    Spectra
    References
    Synthesis Reference

    http://en.wikipedia.org/wiki/Ibuprofen#Synthesis

    General Reference
    1. Zawada ET Jr: Renal consequences of nonsteroidal antiinflammatory drugs. Postgrad Med. 1982 May;71(5):223-30. Pubmed
    2. Townsend KP, Pratico D: Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 2005 Oct;19(12):1592-601. Pubmed
    3. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol. 2005 Dec;58(6):963-7. Pubmed
    4. Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K: Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):324-8. Pubmed
    5. Bergner T, Przybilla B: Photosensitization caused by ibuprofen. J Am Acad Dermatol. 1992 Jan;26(1):114-6. Pubmed
    6. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. Pubmed
    External Links
    ResourceLink
    KEGG DrugD00126
    KEGG CompoundC01588
    PubChem Compound3672
    PubChem Substance46507255
    ChemSpider3544
    ChEBI5855
    ChEMBLCHEMBL521
    Therapeutic Targets DatabaseDAP000780
    PharmGKBPA449957
    IUPHAR2713
    Guide to Pharmacology2713
    HETIBP
    Drug Product Database636525
    RxListhttp://www.rxlist.com/cgi/generic/ibup.htm
    Drugs.comhttp://www.drugs.com/ibuprofen.html
    WikipediaIbuprofen
    ATC CodesC01EB16G02CC01M01AE01M01AE14M02AA13
    AHFS Codes
    • 28:08.04.92
    PDB EntriesNot Available
    FDA labelshow(1.77 MB)
    MSDSshow(73.5 KB)
    Interactions
    Drug Interactions
    Drug
    AcebutololRisk of inhibition of renal prostaglandins
    AcenocoumarolThe NSAID, ibuprofen, may increase the anticoagulant effect of acenocoumarol.
    Acetylsalicylic acidConcomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended.
    AlendronateIncreased risk of gastric toxicity
    AnisindioneThe NSAID, ibuprofen, may increase the anticoagulant effect of anisindione.
    AtenololRisk of inhibition of renal prostaglandins
    Azilsartan medoxomilIncreases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
    BetaxololNonsteroidal Anti-Inflammatory Agents such as ibuprofen may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
    BevantololRisk of inhibition of renal prostaglandins
    BisoprololRisk of inhibition of renal prostaglandins
    BumetanideThe NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, bumetanide.
    CarteololRisk of inhibition of renal prostaglandins
    CarvedilolRisk of inhibition of renal prostaglandins
    ColesevelamBile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
    CyclosporineMonitor for nephrotoxicity
    DicoumarolThe NSAID, ibuprofen, may increase the anticoagulant effect of dicumarol.
    EltrombopagIncreases levels of Ibuprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
    EsmololRisk of inhibition of renal prostaglandins
    Ethacrynic acidThe NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid.
    FurosemideThe NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, furosemide.
    Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
    HomoharringtonineAvoid combination with ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
    LabetalolRisk of inhibition of renal prostaglandins
    LithiumThe NSAID, ibuprofen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
    MethotrexateThe NSAID, ibuprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
    MetoprololRisk of inhibition of renal prostaglandins
    NadololRisk of inhibition of renal prostaglandins
    OxprenololRisk of inhibition of renal prostaglandins
    PenbutololRisk of inhibition of renal prostaglandins
    PindololRisk of inhibition of renal prostaglandins
    PractololRisk of inhibition of renal prostaglandins
    PralatrexateNSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
    PrasugrelCoadministration with NSAIDS used chronically may increase the risk of bleeding.
    PropranololRisk of inhibition of renal prostaglandins
    SotalolRisk of inhibition of renal prostaglandins
    TamoxifenIbuprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Ibuprofen is initiated, discontinued or dose changed.
    TolbutamideIbuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ibuprofen is initiated, discontinued or dose changed.
    TorasemideThe NSAID, ibuprofen, may decrease the diuretic and antihypertensive effect of the loop diuretic, torasemide.
    TrandolaprilThe NSAID, Ibuprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ibuprofen is initiated, discontinued or dose changed.
    TreprostinilThe prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ibuprofen. Monitor for increased bleeding during concomitant thearpy.
    TriflusalThe metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of ibuprofen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
    TrimethoprimThe strong CYP2C9 inhibitor, Ibuprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ibuprofen is initiated, discontinued or dose changed.
    VilazodoneIncreased risk of bleeding with concomitant use of non-steroidal anti-inflammatory drugs with vilazodone.
    VoriconazoleIbuprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ibuprofen is initiated, discontinued or dose changed.
    WarfarinIbuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed.
    Food Interactions
    • Avoid alcohol
    • Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected.
    • Take with food to reduce gastric irritation.

    1. Prostaglandin G/H synthase 2

    Kind: protein

    Organism: Human

    Pharmacological action: yes

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Prostaglandin G/H synthase 2 P35354 Details

    References:

    1. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. Pubmed
    2. Ouellet M, Falgueyret JP, Percival MD: Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem J. 2004 Feb 1;377(Pt 3):675-84. Pubmed
    3. Gallego-Sandin S, Novalbos J, Rosado A, Gisbert JP, Galvez-Mugica MA, Garcia AG, Pajares JM, Abad-Santos F: Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions. Dig Dis Sci. 2004 Sep;49(9):1538-44. Pubmed
    4. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH, Morrow JD: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004 Nov 15;334(2):266-75. Pubmed
    5. Sanchez-Fidalgo S, Martin-Lacave I, Illanes M, Motilva V: Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. Eur J Pharmacol. 2004 Nov 28;505(1-3):187-94. Pubmed
    6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

    2. Prostaglandin G/H synthase 1

    Kind: protein

    Organism: Human

    Pharmacological action: yes

    Components

    Name UniProt ID Details
    Prostaglandin G/H synthase 1 P23219 Details

    References:

    1. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. Pubmed
    2. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6. Pubmed
    3. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71. Pubmed
    4. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. Pubmed
    5. Hillarp A: [Acetylsalicylic acid resistance—clinical diagnosis with unclear mechanism] Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. Pubmed
    6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
    7. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    8. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    9. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    10. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    11. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    12. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    13. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    14. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    15. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    16. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed
    17. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed

    3. Apoptosis regulator Bcl-2

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: modulator

    Components

    Name UniProt ID Details
    Apoptosis regulator Bcl-2 P10415 Details

    References:

    1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. Pubmed

    4. Thrombomodulin

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: modulator

    Components

    Name UniProt ID Details
    Thrombomodulin P07204 Details

    References:

    1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. Pubmed

    5. Tissue-type plasminogen activator

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: negative modulator

    Components

    Name UniProt ID Details
    Tissue-type plasminogen activator P00750 Details

    References:

    1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. Pubmed

    6. Fatty acid-binding protein, intestinal

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: binder

    Components

    Name UniProt ID Details
    Fatty acid-binding protein, intestinal P12104 Details

    References:

    1. Velkov T, Chuang S, Wielens J, Sakellaris H, Charman WN, Porter CJ, Scanlon MJ: The interaction of lipophilic drugs with intestinal fatty acid-binding protein. J Biol Chem. 2005 May 6;280(18):17769-76. Epub 2005 Feb 18. Pubmed

    7. Peroxisome proliferator-activated receptor gamma

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: activator

    Components

    Name UniProt ID Details
    Peroxisome proliferator-activated receptor gamma P37231 Details

    References:

    1. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. Pubmed

    8. Cystic fibrosis transmembrane conductance regulator

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Cystic fibrosis transmembrane conductance regulator P13569 Details

    References:

    1. Devor DC, Schultz BD: Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion. J Clin Invest. 1998 Aug 15;102(4):679-87. Pubmed

    1. Cytochrome P450 2C9

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate inhibitor

    Components

    Name UniProt ID Details
    Cytochrome P450 2C9 P11712 Details

    References:

    1. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. Pubmed
    2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
    3. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
    4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
    5. Carlile DJ, Hakooz N, Bayliss MK, Houston JB: Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol. 1999 Jun;47(6):625-35. Pubmed

    2. Cytochrome P450 2C8

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Cytochrome P450 2C8 P10632 Details

    References:

    1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
    2. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. Pubmed

    3. Cytochrome P450 2C19

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Cytochrome P450 2C19 P33261 Details

    References:

    1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

    4. UDP-glucuronosyltransferase 1-1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    UDP-glucuronosyltransferase 1-1 P22309 Details

    References:

    1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

    5. UDP-glucuronosyltransferase 1-3

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    UDP-glucuronosyltransferase 1-3 P35503 Details

    References:

    1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

    6. UDP-glucuronosyltransferase 1-9

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    UDP-glucuronosyltransferase 1-9 O60656 Details

    References:

    1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

    7. UDP-glucuronosyltransferase 2B4

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    UDP-glucuronosyltransferase 2B4 P06133 Details

    References:

    1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

    8. UDP-glucuronosyltransferase 2B7

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    UDP-glucuronosyltransferase 2B7 P16662 Details

    References:

    1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

    9. Prostaglandin G/H synthase 1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Prostaglandin G/H synthase 1 P23219 Details

    References:

    1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. Pubmed

    10. Prostaglandin G/H synthase 2

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Prostaglandin G/H synthase 2 P35354 Details

    References:

    1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. Pubmed

    1. Serum albumin

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Components

    Name UniProt ID Details
    Serum albumin P02768 Details

    References:

    1. Yamasaki K, Rahman MH, Tsutsumi Y, Maruyama T, Ahmed S, Kragh-Hansen U, Otagiri M: Circular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen. AAPS PharmSciTech. 2000 May 14;1(2):E12. Pubmed

    1. Solute carrier organic anion transporter family member 2B1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 2B1 O94956 Details

    References:

    1. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. Pubmed

    2. Multidrug resistance protein 1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Multidrug resistance protein 1 P08183 Details

    References:

    1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. Pubmed

    3. Multidrug resistance-associated protein 4

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Multidrug resistance-associated protein 4 O15439 Details

    References:

    1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. Pubmed

    4. Multidrug resistance-associated protein 1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Multidrug resistance-associated protein 1 P33527 Details

    References:

    1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. Pubmed

    5. Solute carrier organic anion transporter family member 1A2

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 1A2 P46721 Details

    References:

    1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. Pubmed

    6. Solute carrier family 22 member 6

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Solute carrier family 22 member 6 Q4U2R8 Details

    References:

    1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. Pubmed
    2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. Pubmed
    3. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. Pubmed
    4. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. Pubmed

    7. Solute carrier family 22 member 8

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Solute carrier family 22 member 8 Q8TCC7 Details

    References:

    1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. Pubmed
    2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. Pubmed
    3. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. Pubmed

    8. Solute carrier family 22 member 11

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Solute carrier family 22 member 11 Q9NSA0 Details

    References:

    1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. Pubmed
    2. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. Pubmed

    Comments
    Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13